Abatacept and its use for the treatment of rheumatoid arthritis in the Czech Republic – data from the ATTRA registry
Authors:
P. Horák 1; M. Skácelová 1; K. Hejduk 2
; K. Pavelka 3
Authors place of work:
III. interní klinika – nefrologická, revmatologická, endokrinologická, Lékařská fakulta Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc, 2Institut biostatistiky a analýz, Masarykova univerzita v Brně, 3Revmatologický ústav Praha, 1. Lékařská
1
Published in the journal:
Čes. Revmatol., 20, 2012, No. 4, p. 163-169.
Category:
Original Papers
Summary
The Czech national registry ATTRA collects the data of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopatic arthritis treated with biological drugs. ATTRA is a prospective centralized computerized registry of patients and collects the data on efficacy, safety and quality of life. Currently, abatacept has the position of a second line agent for RA which can be prescribed after a failure of at least one TNFα inhibitor. A total of 162 patients with RA treated by abatacept were included into the current analysis with the mean age of 51.0±12.2 (median 53.1, 19-74 years). The mean disease duration was 14±9.1, median 11.3 years (0-41). One hundred and thirty patients (80.2%) were females. The mean DAS28 at week 0 was 5.9±1.1, at week 16 4.1±1.4, at week 24 3.8±1.2, at week 36 3.6±1.3 and at week 52 3.5±1.2. DAS28 remission was achieved at week 0 in 0.6%, at week 16 in 15.8%, at week 24 in 10%, at week 36 20.9% and at week 52 20.8%. Patients with DAS28 <2.6 (remission) at week 16 had the DAS28 <2.6 also at the week 52 in 58.3% of cases. Patients with DAS28 >5.1 (high disease activity) at the week 16 had DAS28 >5.1 at the week 52 in 41.7%. One year on treatment survival was 82%. Altogether 50 non-serious adverse events (AE) were reported in 36 patients (22%) and 11 serious AE in 10 patients (6%) with most common AE being infections (31) and skin rashes (5) and just one non-serious allergic reaction was reported. Data from registry confirms a good overall efficacy and safety and a very good on-drug survival of abatacept.
Key words:
rheumatoid arthritis, registries, abatacept
Zdroje
1. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-1915.
2. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561–569.
3. Tegzová D, Vencovsky J, Dusek L, Pavelka K. Clinical register of TNF alpha blocking therapy of Czech rheumatologic society. Project ATTRA. Results of study: Clinical efficacy and safety. Ann Rheum Dis 2004; 63(Suppl.1) S263.
4. Prevoo MLL, van ‘t Hof MA, Kuper HH, et al. Modified disease activity scores that includes twenty eight- joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–48.
5. Van Gestel AM, Prevoo MLL, van ‘t Hof MA, et al. Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996; 39:34-40.
6. Prevoo MLL, van Gestel AM, van ‘t Hof MA, et al. Remission in a prospective study of patients with rheumatoid arthritis. Br J Rheumatol 1996;35:1101–1105.
7. The EuroQol Group.EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
8. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993;306:1437-1440.
9. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-1353.
10. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 2263–2271.
11. Kremer JM, Genant H, Moreland L, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144: 865–876.
12. Burmester GR. remission. Nat Rev Rheumatol 2012. [Epub ahead of print] doi: 10.1038/nrrheum.2011.201.
13. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor in inhibition. N Engl J Med 2005;353:1114-1123.
14. Genovese MC, Schiff M, Luggen M, et al. Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial. Arthritis Rheum 2006; 54(Suppl. 9)S247.
15. Dougados M, Schmidely N, Le Bars M, et al. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Ann Rheum Dis 2009;68: 484-489.
16. Westhovens R, Luggen M, Russell A, et al. Abatacept provides durable improvements in RA disease status and a consistent safety profile through 3 years in the aim and attain trials. Rheumatology 2008; 47 (Suppl.2)S46.
17. Emery P, Kremer JM, Moreland R, et al. Long-term efficacy and safety of abatacept through 5 years of treatment in rheumatoid arthritis patients with an inadequate response to methotrexate. Rheumatology 2008, 47 (Suppl.2) S48.
18. Kremer JM, Russell AS, Emery P, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011;70: 1826–1830.
19. Schiff M, Bessette L. Evaluation of abatacept in biologic-naēve patients with active rheumatoid arthritis. Clin Rheum 2010;29: 583-519.
20. Vital EM, Emery P. Abatacept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2006; 2: 365–375.
21. Russel AS, Wallenstein GV, Li T, et al. Abatacept Improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis 2007;66:189-194.
22. Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62:22-32.
23. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate Ann Rheum Dis 2008;67:1096-1103.
24. Schiff M, Keiserman M, Codding C, et al. The efficacy and safety of abatacept or infliximab in RA patients with an inadequate response to MTX: results from a 1-year double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2006; 54 (Suppl.1)S43.
25. Schiff M, Pritchard C, Teng J, et al. The safety of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti-TNF therapy: results from the ARRIVE trial. Ann Rheum Dis 2007; 66 (Suppl. 2) S89.
26. Smitten A, Simon R, Qi K, et al. Hospitalized infections in the abatacept RA clinical development program: An epidemiological assessment with > 10,000 person-years of exposure. Arthritis Rheum 2008, 58(Suppl.)S786-S787.
27. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006; 54:2807–2816.
28. WHO: The evaluation of drugs: whose responsibility? CIOMS Round Table Conference, October 1968. WHO Chron. 1969;23:256-263.
29. Singh JA, Wells GA, Christenses R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011:16;2:CD008794
30. Gottenberg JE, Ravaud P, Bardin T, et al. Prospective follow-up of abatacept treatment in 920 patients with refractory rheumatoid arthritis: Tolerance and efficacy data from French ORA (Orencia and rheumatoid arthritis) registry. Ann Rheum Dis 2010;69(Suppl3) S386.
31. CastaĖeda S, Martínez Calatrava MJ, Herrero-Beaumont G. [Alternatives in the treatment of rheumatoid arthritis: reasons for using abatacept.]Rev Clin Esp. 2011[Epub ahead of print]
32. Souhrn údajů o přípravku: Orencia. http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-Product_Information/human/000701/WC500048935.pdf, 8.2.2012.
Štítky
Dermatology & STDs Paediatric rheumatology RheumatologyČlánok vyšiel v časopise
Czech Rheumatology
2012 Číslo 4
Najčítanejšie v tomto čísle
- Adult onset Still’s disease – a case report
- Osteoimmunology
- Genes of major histocompatibility complex are not only transplantation antigens
- Abatacept and its use for the treatment of rheumatoid arthritis in the Czech Republic – data from the ATTRA registry